ClinicalTrials.gg
CompletedNCT06916156Updated Oct 2, 2025

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants

A Phase 1 interventional study of ANT3310 and Meropenem in Pharmacokinetics Study on Healthy Volunteers Adults, sponsored by Antabio. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Antabio · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, non-randomized, single-center, repeated i.v. doses, Phase 1 trial to evaluate the pharmacokinetics, safety, and tolerability of a combination of MEM-ANT3310 in healthy adult female and male participants who will undergo a single bronchoalveolar lavage (BAL) via a standardized fiberoptic bronchoscopy to evaluate and compare the pharmacokinetics characteristics of ANT3310 and meropenem (MEM) in plasma and epithelial lining luid (ELF).

Read the detailed description

There will be 25 participants enrolled in the study. Each participant will receive a total of 3 doses of MEM-ANT3310, infused intravenously over 3 hours every 8 hours. Each participant will undergo a single bronchoscopy at the assigned BAL sampling time. Blood samples will be collected. Participants will be monitored for adverse events from study center admittance through the EoS visit.

02

Conditions studied

  • Pharmacokinetics Study on Healthy Volunteers Adults

Keywords

  • healthy volunteers
  • Bronchoalveolar lavage (BAL) study
03

In context

Lead sponsor

Antabio is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed in compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Participants must be 18 to 55 years of age, both inclusive, at the time of signing the informed consent.
  • (BMI) within the range 18.0-32.0 kg/m2 (both inclusive) and body weight > 50.0 kg (110 Ibs) at Screening.
  • use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Healthy participants as defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, 12-lead , vital signs, physical examination, spirometry at Screening ( > 80% of predicted), and clinical laboratory tests at Screening and Day -1.
  • Healthy participants with vital signs at Screening and Day -1 within the normal ranges: tympanic body temperature: ≥ 35.5°C and ≤ 37.5°C; resting pulse rate ≥ 50 beats per minute (bpm) and ≤ 100 bpm; systolic blood pressure (SBP) ≥ 90 and ≤ 139 mmHg, diastolic blood pressure (DBP) ≥ 50 and ≤ 89 mmHg, taken in supine position after resting at least 5 minutes. On Day -1, blood pressure and pulse rate need to be within the normal ranges or not range, as per investigator's judgement.
  • Individualized estimated (eGFR): [(CKD-EPI ÷ 1.73) × BSA] ≥ 90 mL/min and \< 160 mL/min for males or \< 150 mL/min for females at Screening.
  • Sufficient venous access for i.v. infusion and PK samplings.

Exclusion criteria

Exclusion Criteria:

  • History of any gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrine, hematologic, neuromuscular or allergic disease(s), metabolic disorder, cancer (may have had basal or squamous cell carcinoma of skin or cervix so long as surgically removed or deemed cured by cryotherapy, laser therapy, conization, etc, with stability for the past two years).
  • History or presence of chronic pulmonary disease.
  • Medical disorder, condition, or history of such that would - in the opinion of the Investigator - compromise the participant's ability to participate in this study.
  • Presence of any acute illness, including febrile illness with temperature > 37.8°C (> 100.0°F), within 7 days of Baseline (Day -1 to Day 1).
  • Known severe allergies, non-allergic drug reactions, or multiple drug allergies requiring intranasal or systemic during any time of the year or history of any anaphylactic reaction.
  • Known to meropenem and or ANT3310 or any of the of the infusion solution.
  • Known history of clinically significant hypersensitivity or urticaria, or severe allergic reaction to β-lactam antibiotics (i.e., penicillin, cephalosporin, carbapenem, or monobactam).
  • History of significant bleeding within the past 3 months.
  • History of COVID-19 within three (3) months prior to Screening.
  • History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders.
  • History of Gilbert syndrome.
  • History of any severe antibiotic-associated superinfections, such as Clostridium difficile colitis and/or frequent fungal vaginal infections.
  • to bronchoalveolar lavage or suspected intolerability to medications necessary for bronchoscopy, hypoxemia, reactive airway disease or asthma, unstable angina or acute myocardial infarction in the last 6 months, heart failure, and severe hemostatic alterations. Anatomical or anticipated technical difficulties that would prevent bronchoscopy or BAL procedure. Allergies to lidocaine.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    ANT3310 and Meropenem (MEM)

    Each participant will receive a total of 3 doses of MEM-ANT3310, infused intravenously over 3 hours every 8 hours (i.e., 0 hour, 8 hours, and 16 hours relative to start of the first infusion).

    Drug: ANT3310 · Drug: Meropenem

Interventions

  • ANT3310 will be administered in combination with Meropenem. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.

  • Meropenem will be administered in combination with ANT3310. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentrations (Cmax) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  2. Area under the concentration-time curve from 0 to 8 hours post-dose (AUC0-8h) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  3. Percent penetration of ANT3310 and Meropenem in epithelial lining fluid (ELF) after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    ratio (%) of AUC0-8h of ELF-to-plasma for ANT3310 and Meropenem

    Time frame: From pre-dose to 8 hours post-last-dose

  4. Time from dosing to maximum observed plasma concentration (tmax) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  5. Area under the concentration-time curve from time 0 to infinity (AUC0-inf) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  6. Apparent terminal elimination half-life (t1/2λz) of ANT3310 and Meropenem in plasma after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  7. Terminal phase elimination rate constant (λz) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  8. Apparent total body clearance at steady-state (CLss) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  9. Apparent volume of distribution at steady-state (Vss) of ANT3310 and Meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma

    Time frame: From pre-dose to 8 hours post-last-dose

  10. Apparent elimination half-life (t1/2,ELF) of ANT3310 and Meropenem in ELF after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in ELF

    Time frame: From pre-dose to 8 hours post-last-dose

Secondary outcomes

  1. Number and severity of treatment-emergent adverse event (TEAE) to evaluate the safety and tolerability of ANT3310 and meropenem after repeated i.v. infusions of a combination of ANT3310 and Meropenem

    Percentage of participants experiencing ≥ one TEAE by seriousness, intensity, and relatedness from baseline through end of study visit

    Time frame: From Day 1 to Day 11

  2. Number of participants who discontinue due to a TEAE.

    Percentage of participants who discontinue due to a TEAE.

    Time frame: From Day 1 to Day 11

  3. Number of participants with clinically significant abnormal values for safety laboratory tests at least once post-dose

    Percentage of participants with clinically significant abnormal values for safety laboratory tests at least once post-dose

    Time frame: From Day 1 to Day 11

  4. Number of participants with clinically significant abnormal values for vital signs (blood pressure, pulse rate, and body temperature) measurement at least once post-dose

    Percentage of participants with clinically significant abnormal values for vital signs (blood pressure, pulse rate, and body temperature) measurement at least once post-dose

    Time frame: From Day 1 to Day 11

  5. Number of participants with clinically significant abnormal values for safety electrocardiogram (ECG) parameters at least once post-dose

    Percentage of participants with clinically significant abnormal values for safety electrocardiogram (ECG) parameters at least once post-dose

    Time frame: From Day 1 to Day 11

  6. Number of infusion site reactions to assess local venous tolerability

    Time frame: From Day 1 to Day 11

07

Study locations

1 site
  • Pulmonary Associates, PA
    Phoenix, Arizona 85032, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Aug 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 8, 2025
StartActual
Apr 28, 2025
Primary completionActual
Aug 14, 2025
CompletionActual
Aug 19, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06916156
Lead sponsor
Antabio
Collaborators
Clinartis
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 28, 2025
Primary completion
Aug 14, 2025
Completion
Aug 19, 2025
Last update
Oct 2, 2025

Study contacts

J. Burr Ross, MD
principal investigator · Pulmonary Associates, PA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pilabactam sodium

Start the discussion